Genmab Announces Leadership Transition as Chief Legal Officer Birgitte Stephensen Retires, Greg Mueller Appointed Successor Genmab A/S (Nasdaq: GMAB), a leading international biotechnology company focused on antibody-based therapeutics for cancer and other serious diseases, today announced a major leadership transition…
Riliprubart Receives Orphan Drug Designation in Japan for Chronic Inflammatory Demyelinating Polyneuropathy Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to riliprubart, an investigational monoclonal antibody that targets activated C1s in the…
Roche Announces Key Leadership Transitions Within Enlarged Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced significant changes to its leadership team, as two esteemed members of its enlarged Corporate Executive Committee prepare to retire. Dr. Johannes (Hans)…
AbbVie to Acquire Capstan Therapeutics to Advance In Vivo CAR-T for Autoimmune Diseases AbbVie and Capstan Therapeutics have announced a definitive agreement for AbbVie to acquire Capstan in a move that underscores AbbVie’s strategic commitment to pioneering next-generation immunology therapies.…
Incyte Appoints Bill Meury as President and CEO, Succeeding Hervé Hoppenot Amid Strategic Leadership Transition In a pivotal leadership transition that marks a new chapter in its corporate journey, Incyte Corporation , a leading global biopharmaceutical company, announced today the…
WuXi AppTec’s Nantong Facility Wins 2025 Architizer A+Award for Excellence in Human-Centered Industrial Design WuXi AppTec, a globally recognized provider of research, development, and manufacturing services for the pharmaceutical and life sciences industries, has proudly announced that its Nantong facility…
BeOne Medicines Receives Positive CHMP Opinion for New Film-Coated Tablet Formulation of BRUKINSA® (zanubrutinib), Paving the Way for European Market Approval BeOne Medicines Ltd. a globally operating oncology-focused biopharmaceutical company, has taken a significant step forward in expanding patient access…
Sanofi’s Riliprubart Receives U.S. FDA Orphan Drug Designation for Antibody-Mediated Rejection in Solid Organ Transplantation The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to riliprubart, an investigational immunology therapy developed by Sanofi, for the treatment…
Rebuilding Trust and Reshaping Global Health Finance: H20 Summit Lays Groundwork for G20 Health Agenda From June 19 to 20, global leaders in health and development converged in Geneva for the annual Health20 (H20) Summit. The high-level event, organized by…
Merck Awards 2025 North American Advance Biotech Grant to Neoclease for AI-Driven Parkinson’s Gene Editing Therapy Merck, a global leader in science and technology, has officially named Neoclease as the recipient of its 2025 North American Advance Biotech Grant, recognizing…
FDA Approves ANDEMBRY (garadacimab-gxii) The First Once-Monthly Prophylactic HAE Therapy Targeting Factor XIIa CSL a leading biotechnology company with a strong track record of developing innovative medicines for patients with rare and serious disorders, today announced that the U.S. Food…
Dapirolizumab Pegol Shows Disease Activity Reduction and Fatigue Improvement in SLE at EULAR 2025 UCB and Biogen today presented additional and detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel, Fc-free, anti-CD40 Ligand (anti-CD40L)…